The Collaboration Agreement with Siemens was terminated. UBI entered into a Commercial and Distribution Agreement and other definitive agreements with Siemens. Pursuant to these agreements, UBI acquired certain assets of Siemens and amongst other things enables UBI the right to pursue partnership and distribution opportunities for point-of-care coagulation products outside of its arrangement with Siemens.
LifeScan gave notice and exercised its right to “convert” its obligation to pay quarterly service fees to UBI. Accordingly, UBI will not receive any further quarterly service fees beyond 2018.
UBI acquires Hemostasis Reference Laboratory business.
Siemens Healthcare Diagnostics receives CE Mark approval and launches the Xprecia Stride™ Coagulation Analyser in Europe. The product has since been launched in key markets including US, Europe, Asia Pacific and The Middle East.
UBI signs long term supply and manufacturing agreement with Siemens Healthcare Diagnostics for manufacture of biosensors for point-of-care (POC) coagulation testing.
LifeScan’s UBI-designed biosensor strip and meter system, OneTouch® Verio®, receives initial regulatory clearance to sell in Europe. The product has since been rolled out globally.
UBI lists on the Australian Securities Exchange. UBI commences establishment of world class biosensor manufacturing facilities at Rowville, Victoria, Australia.
UBI completes deal with LifeScan, Inc, (a Johnson & Johnson company). LifeScan takes ownership of electrochemical cell technologies and grants UBI a licence for these
technologies outside the field of diabetes and blood glucose management generally. LifeScan engages UBI to develop a new blood glucose test.
Universal Biosensors, Inc (UBI) incorporated in Delaware, US. Australian subsidiary, Universal Biosensors Pty Ltd, formed.